RION (6823) FY2027 Q1 Earnings Report

Quick View

Executive Summary

Revenue and earnings increased, with Operating Income significantly outpacing revenue growth; the improvement in profitability was the key feature of the current period's results. Revenue was ¥68.85B (+3.9% YoY), Operating Income was ¥9.88B (+19.2%), Ordinary Income was ¥10.01B (+17.3%), and Net Income was ¥6.87B (+15.6%). While the Medical Equipment and Environmental Equipment Businesses drove revenue and earnings growth, the core Particle Measurement Instruments Business experienced declines in both revenue and earnings. Operating leverage resulting from the containment of SG&A expenses was the primary driver of earnings growth.

Factors Affecting Performance

【Revenue】Revenue was ¥68.85B, an increase of +3.9% YoY. Revenue increased in the Medical Equipment Business to ¥30.59B (+5.5% YoY, 44.4% mix) and in the Environmental Equipment Business to ¥13.88B (+12.4% YoY, 20.2% mix), while revenue in the core Particle Measurement Instruments Business declined to ¥24.39B (-2.3% YoY, 35.4% mix). Within the Medical Equipment Business, hearing aids performed well at ¥26.30B (+9.7% YoY), while medical testing equipment declined to ¥4.29B (-14.7% YoY).

【Profit and Loss】Gross profit was ¥34.33B, and the gross margin improved to 49.9% from 49.6% in the same period last year. SG&A expenses declined 0.7% YoY to ¥24.44B. As expense control amid revenue growth generated operating leverage, Operating Income increased to ¥9.88B (+19.2% YoY), and the Operating Income margin was 14.4% (12.5% in the same period last year). Non-operating income and expenses resulted in only a small net gain, mainly from dividend income of ¥0.2B, and the increase in Ordinary Income to ¥10.01B (+17.3% YoY) was primarily attributable to improved profitability in the core business. Extraordinary losses were minimal, consisting only of a ¥0.01B loss on disposal of fixed assets, and Net Income was ¥6.87B (+15.6% YoY). In conclusion, both revenue and earnings increased.

Segment Analysis

The Particle Measurement Instruments Business reported revenue of ¥24.39B (-2.3% YoY) and Operating Income of ¥5.86B (-5.6% YoY). Although it maintained the highest margin among the three businesses at 24.0%, its contribution to consolidated Operating Income is approximately 59%; therefore, its decline in both revenue and earnings is the largest factor affecting consolidated earnings. The Medical Equipment Business reported revenue of ¥30.59B (+5.5% YoY) and Operating Income of ¥2.86B (+28.6% YoY), with a margin of 9.3%, recording increases in both revenue and earnings mainly due to growth in hearing aids. The Environmental Equipment Business reported revenue of ¥13.88B (+12.4% YoY) and Operating Income of ¥1.17B, turning profitable from a loss of ¥0.13B in the same period last year. It should be noted that continued revenue declines in the high-margin Particle Measurement Instruments Business would limit the potential for improvement in the consolidated profit margin.

Key Financial Metrics

【Profitability】The Operating Income margin was 14.4%, improving by approximately +1.9pt YoY, while the Net Income margin also improved to 10.0% (9.0% in the same period last year). The gross margin was 49.9%, slightly up from 49.6% in the previous year, and the SG&A ratio declined to 35.5%, indicating that expense control supported the improvement in profit margins.【Cash Flow Quality】Comprehensive Income was ¥10.6B, exceeding Net Income of ¥6.9B. Unrealized gains on securities of ¥2.8B and foreign currency translation adjustments of ¥1.0B contributed to the increase, indicating that the quality of earnings in the current period was affected to a certain extent by valuation gains.【Investment Efficiency】Annualized ROE was 7.8%. Although the improvement in the Net Income margin contributed positively, the total asset turnover ratio remained low, while a substantial equity base and large cash and deposits and inventory balances constrained further improvement in capital efficiency.【Financial Soundness】The Equity Ratio was extremely high at 82.3%, and current assets of ¥259.0B substantially exceeded current liabilities of ¥52.1B. Goodwill was ¥7.7B, only 2.2% of net assets, indicating limited financial risk.

Cash Flow Analysis

As the cash flow statement was not disclosed in these results, cash trends are analyzed based on changes in the balance sheet. Cash and deposits were ¥98.7B, increasing by +¥13.1B (+15.1%) from ¥85.6B in the previous year, resulting in greater liquidity on hand. Meanwhile, accounts receivable and notes receivable were ¥45.1B, down from ¥54.5B in the previous year, suggesting that progress in receivables collection was one factor behind the increase in cash and deposits. Inventories were ¥79.7B, slightly higher than in the previous year, indicating that inventory levels remain elevated. With a robust financial base comprising an Equity Ratio of 82.3% and current assets approximately 5 times current liabilities, no concerns regarding liquidity are evident.

Quality of Earnings

The current period's earnings were barely affected by extraordinary items and can be viewed as having been generated by recurring business activities. Extraordinary losses consisted only of a ¥0.01B loss on disposal of fixed assets, while non-operating income and expenses resulted in only a small net gain, mainly from dividend income of ¥0.2B. No significant one-time uplift or drag was identified in the progression from Operating Income to Net Income. On the other hand, Comprehensive Income of ¥10.6B exceeded Net Income of ¥6.9B, with the difference attributable to fair-value items such as valuation differences on other securities of ¥2.8B and foreign currency translation adjustments of ¥1.0B. These represent valuation gains and losses caused by market fluctuations and should be considered separately from the earnings power of the core business. No significant unusual items were identified in the composition of cost of sales or SG&A expenses; therefore, the source of earnings growth can be considered to be recurring factors, namely SG&A expense control and gross margin improvement.

Earnings Forecast and Guidance

The full-year earnings forecasts remain unchanged at Revenue of ¥297.0B (+4.2% YoY), Operating Income of ¥47.0B (+7.7% YoY), and Ordinary Income of ¥47.5B (+6.9% YoY). Progress rates based on Q1 results were 23.2% for Revenue, 21.0% for Operating Income, 21.1% for Ordinary Income, and 19.9% for Net Income, all below the simple quarterly allocation of 25%. In particular, progress on the earnings front lagged revenue progress, indicating that results will need to build from Q2 onward; however, as of the current quarter, no revisions have been made to the earnings or dividend forecasts.

Shareholder Returns

The full-year dividend forecast is ¥90 per share, unchanged from the initial forecast. Based on projected full-year EPS of ¥279.8, the forecast Payout Ratio is approximately 32.2%, remaining below the general benchmark of 60%. Given the financial base of equity of ¥352.4B, cash and deposits of ¥98.7B, and an Equity Ratio of 82.3%, the continuation of dividends is considered to be well supported from both earnings and financial perspectives.

Risk Factors

1. Decline in revenue and earnings in the core business: Revenue in the Particle Measurement Instruments Business declined -2.3% YoY, while segment profit declined -5.6%. As the business accounts for approximately 59% of consolidated Operating Income and has the highest margin at 24.0%, any delay in its recovery would have a significant impact on consolidated profitability.

2. Inventory and working capital efficiency: Inventories of ¥79.7B account for 18.6% of total assets, while inventory days are 211 days on an annualized basis and the CCC is 223 days on an annualized basis. Although liquidity risk is low due to the strong financial position, there is substantial room for improvement in terms of capital efficiency and future cash generation capacity.

3. Quality assurance costs: The product warranty provision was ¥2.99B, or 4.3% of revenue. Although it was nearly flat compared with ¥2.98B in the same period last year, it remains at a high level. In the Medical Equipment and Measurement Instruments Businesses, increases in quality- and warranty-related costs could affect the sustainability of profit margin improvements.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

Both the Operating Income margin and Net Income margin exceed the industry median, placing profitability in the upper tier of the industry.

Growth and Capital Efficiency

The Revenue growth rate is slightly below the industry median, indicating that top-line growth is relatively moderate compared with the high level of profitability.

※Source: Compiled by the Company

Key Takeaways from the Results

1. The Operating Income margin improved to 14.4%, confirming a trend of earnings growth accompanied by SG&A expense control. However, the core Particle Measurement Instruments Business experienced declines in both revenue and earnings, and the performance of this highest-margin segment remains the largest factor affecting consolidated profitability.

2. Working capital funding requirements, reflected in inventory days of 211 days and a CCC of 223 days, represent a capital efficiency challenge in contrast to the Company's strong financial soundness.

3. Q1 earnings progress against the full-year forecast was approximately 20–21%, below the simple allocation of 25%. However, there were no revisions to the earnings or dividend forecasts, making the accumulation of progress in the second half an item to monitor going forward.

Theoretical Share Price (Reference Value)

Sensitivity: ¥2,842–¥3,008 for a ±1% change in the cost of equity, and ¥2,922–¥2,925 for a ±0.1 change in ω.

Notes:

• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).
• As net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly available data; it is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee the future share price.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting with professionals as necessary.

---End of Report---